Leerink Partners Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $26

Benzinga Newsdesk www.benzinga.com Positive 71.2%

Neg 0% Neu 0% Pos 71.2%

Leerink Partners analyst Asthika Goonewardene initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform rating and announces Price Target of $26.